Triple intraventricular chemotherapy for treatment of relapsed choroid plexus carcinoma

Lau, Grace; Drummond, Julie; Zhukova, Nataliya; Wood, Paul; Janson, Lisa

doi:10.1002/pbc.29094

Cited by 2 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In young patients with metastatic disease, intrathecal chemotherapy (IT) has been used as CNS-directed therapy, and there are accumulating data to suggest this to be an effective administration route in brain tumour patients [ 97 , 98 ]. However, there is no current evidence to show an additional benefit of IT in up-front treatment or in the recurrent setting, although some reported efficacy has been shown in the relapsed CPC [ 21 , 99 ]. In the SIOP CPT 2000 trail, where some metastatic patients had IT araC or IT etoposide, no survival benefit was seen (unpublished, personal communication).…”

Section: Minimising the Impact Of Choroid Plexus Carcinoma And Its Tr...mentioning

confidence: 99%

“…Due to the relative sensitivity of the TP53 mutant cells to methotrexate, this drug is being considered in future CPC protocols trying to improve outcomes in high-risk CPC patients (see Table 1 ) [ 20 ]. Intraventricular chemotherapy has also been used, although more in the context of relapsed disease; however, the evidence for its benefit comes from single case reports [ 21 ]. Radiation therapy is standard practice in children old enough to receive it with minimized late effects.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Approaches to Minimise the Neurodevelopmental Impact of Choroid Plexus Carcinoma and Its Treatment

Adamski,

Langford,

Finlay

2023

Life

View full text Add to dashboard Cite

Choroid plexus carcinomas (CPC) are rare aggressive tumours that primarily affect very young children. Treatment for CPC typically involves a combination of surgery, chemotherapy, and radiation therapy. Whilst considered necessary for a cure, these therapies have significant neurocognitive consequences for patients, negatively impacting cognitive function including memory, attention, executive functioning, and full-scale intelligence quotients (FSIQ). These challenges significantly impact the quality of life and ultimately socioeconomic parameters such as the level of educational attainment, marital status, and socioeconomic status. This review looks at the tumour- and treatment-related causes of neurocognitive damage in CPC patients and the progress made in finding strategies to reduce these. Opportunities to mitigate the neurodevelopmental consequences of surgery, chemotherapy, and radiation therapy are explored in the context of CPC treatment. Evaluation of the pathological and biological mechanisms of injury has identified innovative approaches to neurocognitive protection and neurorehabilitation, which aim to limit the neurocognitive damage. This review aims to highlight multiple approaches physicians can use when treating young children with CPC, to focus on neurocognitive outcomes as a measure of success.

show abstract